Monte Rosa Therapeutics Inc

NASDAQ GLUE

Data sourced from

and

Daily

Download Data

Monte Rosa Therapeutics Inc Price to Earnings Ratio (P/E) on June 03, 2024: -6.92

Monte Rosa Therapeutics Inc Price to Earnings Ratio (P/E) is -6.92 on June 03, 2024, a -120.62% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.

Monte Rosa Therapeutics Inc 52-week high Price to Earnings Ratio (P/E) is -0.00 on March 11, 2024, which is 99.96% above the current Price to Earnings Ratio (P/E).
Monte Rosa Therapeutics Inc 52-week low Price to Earnings Ratio (P/E) is -9.04 on May 17, 2024, which is -30.65% below the current Price to Earnings Ratio (P/E).
Monte Rosa Therapeutics Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is -3.21.

NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO	Dr. Markus Warmuth M.D.
IPO Date	June 24, 2021
Location	United States
Headquarters	645 Summer Street, Boston, MA, United States, 02210
Employees	130
Sector	Healthcare
Industry	Biotechnology

Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Key trends